bioAffinity Technologies, Inc. (BIAF) Income Statement
BIAF 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBIAF revenue and net income
Where BIAF's revenue goes
2025Each bar shows an amount and its share of revenue. BIAF kept −242.0% of revenue as net income.
BIAF profit margins
BIAF growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −34.2% | +986.6% | — | — |
| Gross profit | −57.7% | +591.0% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BIAF quarterly EPS vs estimates
bioAffinity Technologies beat the analyst EPS estimate in 1 of the last 5 quarters. Next report: November 13, 2026.
BIAF income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4,803 | $1,306 | $0 | $0 |
| Cost of revenue | $4.7M | $6.0M | $1.7M | $467 | $4,817 | $22,242 | $40,278 |
| Gross profit | $1.4M | $3.4M | $791,615 | $4,336 | −$4,817 | −$22,242 | −$40,278 |
| Research & development | $2.1M | $1.8M | $1.7M | $1.5M | $1.1M | $1.6M | $1.9M |
| Sales, general & admin | $9.9M | $9.9M | $6.8M | $2.7M | $1.1M | $994,343 | — |
| Total operating expenses | $12.0M | $12.3M | $8.8M | $4.0M | $2.2M | $2.6M | $3.1M |
| Operating income | −$10.6M | −$9.0M | −$8.0M | −$4.0M | −$2.2M | −$2.6M | −$3.1M |
| Interest income | $23,385 | $17,610 | $148,418 | $46,708 | $424 | $1,073 | — |
| Interest expense | $44,372 | $92,475 | $37,125 | $2.5M | $1.0M | $382,171 | $214,834 |
| Income before taxes | −$14.9M | −$9.0M | −$7.9M | −$8.2M | −$6.3M | −$7.3M | −$3.3M |
| Income taxes | $44,042 | $11,650 | $20,993 | $2,459 | $1,950 | $2,750 | $3,200 |
| Net income | −$14.9M | −$9.0M | −$7.9M | −$8.2M | −$6.3M | −$7.3M | −$3.3M |
| EBITDA | −$14.3M | −$8.3M | −$7.6M | −$5.6M | −$5.3M | −$6.9M | −$3.0M |
| EPS (diluted) | −$15.53 | −$0.80 | −$0.64 | −$1.87 | — | — | — |
| Gross margin | 23.2% | 36.1% | 31.3% | 90.3% | −368.8% | — | — |
| Operating margin | −171.6% | −95.6% | −314.9% | −83,511.5% | −168,975.7% | — | — |
| Net margin | −242.0% | −96.6% | −313.5% | −169,771.2% | −484,411.4% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $1.6M | $1.4M | $1.3M | $1.9M | $2.2M | $2.4M | $2.4M | $2.4M | $2.2M | $298,484 |
| Cost of revenue | $4.8M | $1.0M | $1.3M | $1.1M | $1.0M | $1.4M | $1.7M | $1.4M | $1.4M | $1.6M | $1.7M | $74,704 |
| Gross profit | −$3.3M | $308,373 | $301,211 | $390,495 | $252,881 | $485,737 | $491,795 | $910,228 | $989,942 | $832,950 | $548,497 | $223,780 |
| Research & development | $361,575 | $349,707 | $668,813 | $473,900 | $440,651 | $505,739 | $518,186 | $368,202 | $453,895 | $442,599 | $528,169 | $436,798 |
| Sales, general & admin | $2.9M | $3.2M | $3.0M | $2.2M | $2.2M | $2.5M | $2.5M | $2.4M | $2.5M | $2.2M | $2.2M | $2.0M |
| Total operating expenses | $4.8M | $3.9M | $3.4M | $2.7M | $2.8M | $3.1M | $3.4M | $2.9M | $3.1M | $2.8M | $4.6M | $2.5M |
| Operating income | −$3.3M | −$3.6M | −$3.1M | −$2.3M | −$2.5M | −$2.6M | −$2.9M | −$2.0M | −$2.1M | −$1.9M | −$2.3M | −$2.3M |
| Interest income | $3,358 | $10,026 | $19,730 | $1,088 | $2,025 | $542 | $4,069 | $2,228 | $5,186 | $6,127 | $12,160 | $27,193 |
| Interest expense | $11,688 | $14,722 | $13,069 | $5,358 | $10,460 | $15,485 | $25,045 | $21,631 | $22,249 | $23,550 | $25,324 | $8,785 |
| Income before taxes | −$3.4M | −$3.6M | −$3.1M | −$5.0M | −$4.0M | −$2.7M | −$3.0M | −$2.0M | −$2.1M | −$2.0M | −$2.4M | −$2.3M |
| Income taxes | — | — | $3,181 | $3,182 | $28,984 | $8,695 | −$23,300 | $2,559 | $5,419 | $3,672 | — | $2,294 |
| Net income | −$3.4M | −$3.6M | −$3.1M | −$5.1M | −$4.1M | −$2.7M | −$3.0M | −$2.0M | −$2.1M | −$2.0M | −$2.4M | −$2.3M |
| EBITDA | −$3.3M | −$3.5M | −$3.0M | −$4.9M | −$3.9M | −$2.5M | −$2.8M | −$1.8M | −$1.9M | −$1.8M | — | −$2.2M |
| EPS (diluted) | −$0.64 | −$0.81 | −$10.46 | −$4.74 | −$0.17 | −$0.16 | −$0.19 | −$0.16 | −$0.19 | −$0.26 | $0.00 | −$0.26 |
| Gross margin | −220.8% | 22.8% | 18.9% | 27.0% | 19.9% | 26.2% | 22.3% | 38.7% | 41.3% | 34.6% | 24.8% | 75.0% |
| Operating margin | −220.8% | −267.6% | −196.9% | −158.6% | −198.2% | −141.7% | −133.5% | −84.0% | −87.1% | −80.8% | −105.8% | −768.7% |
| Net margin | −222.8% | −268.6% | −197.0% | −349.3% | −319.9% | −143.5% | −134.4% | −85.1% | −88.0% | −81.5% | −107.2% | −767.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BIAF's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BIAF financial results
In fiscal year 2025 (ended December 31, 2025), bioAffinity Technologies reported revenue of $6.2 million, down 34.2% from the year before. It had a net loss of $14.9 million, a net profit margin of −242.0%. Diluted earnings per share came to −$15.53.
See the BIAF stock overview for the latest quote and news, or the BIAF chart for price history and technical indicators.
BIAF income statement FAQ
What is bioAffinity Technologies's annual revenue?
bioAffinity Technologies reported total revenue of $6.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 34.2% from $9.4 million the previous year.
Is bioAffinity Technologies profitable?
No. bioAffinity Technologies reported a net loss of $14.9 million in fiscal 2025, a net profit margin of −242.0%; its operating margin was −171.6%.
What is bioAffinity Technologies's gross margin?
bioAffinity Technologies's gross margin was 23.2% in fiscal 2025: for every $100 of revenue, bioAffinity Technologies kept $23 after the direct cost of its products and services.
How much does bioAffinity Technologies spend on research and development?
bioAffinity Technologies spent $2.1 million on research and development in fiscal 2025, 33.9% of revenue.
What are bioAffinity Technologies's earnings per share?
bioAffinity Technologies earned $-15.53 per diluted share in fiscal 2025, compared with $-0.80 a year earlier.
When will bioAffinity Technologies report its next earnings?
bioAffinity Technologies is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does bioAffinity Technologies's fiscal year end?
bioAffinity Technologies's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.